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Abstract
Survivin is an inhibitor of apoptosis overexpressed in different types of tumors and
undetectable in most terminally differentiated normal tissues. In the current study,
we sought to evaluate the in vitro theranostic properties of a molecular beacon-
oligodeoxynucleotide (MB) that targets survivin mRNA. We used laser scanning
confocal microscopy to study MB delivery in living cells and real-time PCR and
western blot to assess selective survivin-targeting in human malignant melanoma
cells. We further assess the pro-apoptotic effect of MB by measuring
internucleosomal DNA fragmentation, dissipation of mitochondrial membrane
potential (MMP) and changes in nuclear morphology. Transfection of MB into A375
and 501 Mel cells generated high signal intensity from the cytoplasm, while no
signal was detected in the extracellular environment and in survivin-negative cells
(i.e., human melanocytes and monocytes). MB time dependently decreased
survivin mRNA and protein expression in melanoma cells with the maximum effect
reached at 72 h. Treatment of melanoma cells with MB induced apoptosis by
significant changes in MMP, accumulation of histone-complexed DNA fragments in
the cytoplasm and nuclear condensation. MB also enhanced the pro-apoptotic
effect of standard chemotherapeutic drugs tested at clinically relevant
concentrations. The MB tested in the current study conjugates the ability of imaging
with the pharmacological silencing activity against survivin mRNA in human
melanoma cells and may represent an innovative approach for cancer diagnosis
and treatment.
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Introduction
Cutaneous malignant melanoma is a type of skin cancer that develops in response
to genetic and environmental pressures leading to oncogenic transformation of
normal human melanocytes. Currently, more than one hundred thousand
melanoma skin cancers occur globally each year [1]. Treatment of melanoma by
surgical excision is usually curative only when the tumor is detected early [2],
while survival is poor for patients with advanced disease [3]. This poor prognosis
largely results from resistance to conventional chemotherapy [4] and the lack of
effective treatments that may modify the natural history of the disease [5].
Survivin is a member of the inhibitor of apoptosis (IAP) family [6] that plays a
key role in the regulation of cell division, apoptosis, cell migration and metastasis
[7–9]. Furthermore, survivin is involved in the promotion of angiogenesis and
chemoresistance [9]. Unlike other anti-apoptotic proteins, survivin is undetect-
able in most terminally differentiated normal tissues, while it is overexpressed in
human cancer [10]. For instance, survivin is highly overexpressed in malignant
melanoma cells compared with normal melanocytic nevi and normal differ-
entiated skin tissues [11]. Furthermore, a retrospective analysis performed in
melanoma patients has revealed that survivin up-regulation is correlated with
decreased survival rate, increased relapse, and chemoresistance occurrence [12–
14]. These features make survivin a promising target against which novel anti-
cancer drugs could be developed.
It is widely recognised that therapeutic strategies targeting survivin (e.g.,
antisense oligonucleotides and siRNA) can induce tumor cell death, circumvent
drug resistance and sensitize cancer cells to chemotherapeutic drugs [9]. More
recently, much attention has been directed to molecular beacons (MBs) as
potential theranostic agents [15]. MBs are stem-loop-folded oligodeoxyribonu-
cleotides with fluorophore and quencher dyes conjugated to the opposite ends of
the hairpin. In the absence of the complementary nucleic acid target (mRNA, in
the case of this work), the fluorescence of the fluorophore is quenched by the
closely located quencher [16]. Otherwise, the hybridization with target nucleic
acid opens the hairpin, generates probe-analyte duplex that physically separates
the fluorophore from quencher, allowing a fluorescence signal to be emitted upon
excitation [17, 18].
It has been reported that MB technology may allow assessing gene expression in
vivo with high sensitivity and low background signal and may help to
noninvasively detect cancer in its early stages. Furthermore, MB can also produce
therapeutic effect by binding and down-regulating its target gene [19]. Several
lines of evidence provided by the antisense therapy research, demonstrate that
complementary pairing of a short segment of an exogenous oligonucleotide to
mRNA can have a profound impact on protein expression levels and even cell fate.
In fact, binding of MB to mRNA can trigger RNase H mediated mRNA
degradation [17].
In the current study, we provide evidence of the simultaneous imaging and pro-
apoptotic activities of a previously described MB [20] and demonstrate that such
Survivin-Targeting Molecular Beacon in Melanoma Cells
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effects are associated with selective targeting of survivin mRNA in human
melanoma cells. This approach may represent an innovative strategy for the
development of novel theranostic drugs in human cancer.
Materials and Methods
Cell cultures
The human malignant melanoma A375 cell line (American Type Culture
Collection, Rockville, MD, USA) was cultured at 37 C˚ in a humidified atmosphere
containing 5% CO2 in DMEM supplemented with l-glutamine (2 mM), 10%
heat-inactivated fetal bovine serum (FBS) and 1% (w/v) penicillin/streptomycin
(Sigma-Aldrich, Milan, Italy). The human metastatic melanoma 501 Mel cell line
was a kind gift from Dr. Poliseno (Oncogenomics Unit, Core Research
Laboratory, Istituto Toscano Tumori c/o IFC-CNR, Pisa, Italy). 501 Mel cells were
cultured in the same condition of A375 with glucose supplement. Human
bronchial smooth muscle cells (BSMC; Lonza, Walkersville, MD, USA) were
maintained exactly as recommended by the manufacturer in an optimized
medium containing 5% fetal bovine serum, 5.5 mM glucose, 50 mg/ml
gentamicin, 50 ng/ml amphotericin-B, 5 ng/ml insulin, 2 ng/ml basic fibroblast
growth factor and 0.5 ng/ml epidermal growth factor (SmGM-2 Bullet Kit,
Lonza). Human melanocytes (PromoCell GmbH, Germany) were cultured at 37 C˚
in a humidified atmosphere containing 5% CO2 in Melanocyte Growth Medium
M2 (PromoCell GmbH, Germany). Human monocytes were a kind gift from Dr.
Celi (Department of Surgery, Medical, Molecular, and Critical Area Pathology).
Monocyte isolation was performed as described previously [21]. The procedure
was approved by the local ethics committee at the University of Pisa and was in
accordance with the Declaration of Helsinki. A signed consent was obtained from
all donors.
Drugs
Docetaxel (DTX) and Cisplatin (CisPt) were purchased from Sigma–Aldrich,
Milan, Italy. DTX was dissolved in dimethyl sulfoxide (DMSO) and diluted with
culture medium (DMSO final concentration of 0.0001%, v/v), while CisPt was
dissolved in water.
Transfection
Cells were transfected with 100 nM antisense oligodeoxynucleotides using
Lipofectamine 2000 (Ref. 11668-027, Invitrogen Life Technologies, Carlsbad, CA,
USA), which has been reported to yield high transfection efficiency (<70%) in
A375 cells [22]. A molecular beacon (MB), which targets nucleotides 149–163 of
survivin mRNA, and the other oligodeoxynucleotides were synthesized by IBA
(Go¨ttingen, Germany) [20]. ATTO647N (labs 644 nm, lem 669 nm) and
Blackberry Quencher 650 (lmax,650 nm, useful absorbance between 550 and
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PLOS ONE | DOI:10.1371/journal.pone.0114588 December 11, 2014 3 / 16
750 nm) were used as fluorophore/quencher pair. A fluorescent DNA probe, with
the same oligonucleotide sequence of MB but not structured as a molecular
beacon and labelled only with the ATTO647N dye, was used as control.
Oligonucleotide sequences are listed in Table 1.
In vitro confocal microscopy in living cells
Laser scanning confocal microscopy was carried out by using a microscope
RadiacePLUS (Bio-Rad). Briefly, cells were plated on 35 mm m-dishes (Ibidi
Giemme Snc, Milan, Italy) and treated with 100 nM antisense oligodeoxynu-
cleotides (MB or probe). All observations were done with an oil immersion x 40
Nikon objective lens (NA51.3). Fluorescence was evaluated at different time
points during the transfection (excitation and emission wavelengths of 644 and
669 nm, respectively). Acquired images were processed using the open source
Image-J software.
RT-PCR and quantitative real-time PCR analyses
Total RNA from cells was extracted by using the RNeasy Mini kit, following
manufacturer’s instructions, and reverse-transcribed by the QuantiTect Reverse
Transcription kit (Qiagen, Valencia, CA, USA). RT-PCRs were performed by the
HotStartTaq Master Mix kit (Qiagen, Valencia, CA, USA). Primer sequences are
listed in Table 2. Thermal cycle conditions were as follows: 95 C˚ for 15 min, 35
cycles of denaturation at 95 C˚ for 1 min followed by annealing and extension at
72 C˚ for 1 and 10 min, respectively. Detection of the RT-PCR products was
performed by agarose gel electrophoresis and ethidium bromide staining.
Real-time PCR was performed with SsoFast Eva Green Supermix (Ref. 172-
5201, Bio-Rad, CA, USA). Samples were amplified using the following thermal
profile: 95 C˚ for 30 s, 40 cycles of denaturation at 95 C˚ 15 s followed by annealing
for 30 s and 72 C˚ for 30 s, with a final step at 65 C˚ for 5 s. GAPDH and b-actin
were used as housekeeping genes.
Western blot analysis
Cell lysates were collected after treatments at different time points. Samples
containing the same amount of protein (40 mg) were separated on a 15% SDS-
polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane
(Sigma–Aldrich, Milan, Italy), blocked with 5% non-fat milk in TBE and probed
with specific antibodies. Incubation was performed at 4 C˚ overnight with anti-
survivin (Ref. sc-17779, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
anti-b-actin (Ref. A2228, Sigma–Aldrich, Milan, Italy) antibodies. Membranes
were then washed with blocking solution and incubated with secondary antibodies
conjugated with horseradish peroxidase (Ref. sc-2005, Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Chemiluminescence detection was performed using
Western Blotting Luminol Reagent (Ref. sc-2048, Santa Cruz Biotechnology,
Survivin-Targeting Molecular Beacon in Melanoma Cells
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Santa Cruz, USA), according to the manufacturer’s instructions. Quantification of
proteins on SDS-PAGE gels was performed using ImageJ densitometry software
and signal intensities were normalized to those for b-actin.
Internucleosomal DNA fragmentation
The Cell Death Detection ELISA Kit (Ref. 11774452001, Roche, Mannheim,
Germany) was used for assessing apoptosis in A375 cells treated with MB,
according to the manufacturer’s protocol. Briefly, A375 cells were treated with
100 nM MB at different times. After treatment, 104 cells were lysed and
centrifuged at 2006g for 10 min and the supernatant placed into a streptavidin-
coated microplate. A mixture of anti-histone-biotin and anti-DNA-POD was
added and incubated at room temperature for 2 h. After incubation, unbound
antibodies were removed from the solution and the nucleosomes were quantified
by colour development with substrate. Optical density was measured at 405 nm
with the Infinite M200 NanoQuant instrument (Tecan, Salzburg, Austria).
Mitochondrial membrane potential (DYm)
Changes in mitochondrial membrane potential (DYm) during the early stages of
apoptosis were assayed using the Muse MitoPotential assay (Ref. MCH 100110,
Merck Millipore; Darmstadt, Germany) in A375 cells treated with MB alone or in
combination with Cis-Pt or DTX. Briefly, cells were harvested and the cell pellet
was suspended in assay buffer (105 cells/100 ml). MitoPotential dye working
solution was added and the cell suspension incubated at 37 C˚ for 20 min. After
the addition of Muse MitoPotential 7-AAD dye (propidium iodide) and
incubation for 5 min, changes in DYm and in cellular plasma membrane
Table 1. Oligonucleotide sequences of Molecular Beacon (MB) and probe.
Name Sequence
MB 59-ATTO647N-CGACGGAGAAAGGGCTGCCACG/thiol-(C6)-dT/CG–BBQ-39
Probe 59-ATTO647N-GAGAAAGGGCTGCCA/thiol-39
BBQ: BlackBerry Quencher; ATTO647N: fluorescent label (report). Underlined bases are the ones forming the loop.
doi:10.1371/journal.pone.0114588.t001
Table 2. Primer nucleotide sequences, Ta and amplicon length used for PCR experiments.
Name Primer nucleotide sequences Ta ( C˚) Amplicon lenght
GAPDH 59-GTGAAGGTCGGAGTCAACG- 39 (F) 59 301 pb
59GGTGAAGACGGCCAGTGGACT- 39 (R)
Beta-actin 59- AACTGGAACGGTGAAGGTGAC -39 (F) 61 138 pb
59- GACTTCCTGTAACAACGCATCTC - 39 (R)
Survivin 59- ACCAGGTGAGAAGTGAGGGA -39 (F) 59 309 pb
59- AACAGTAGAGGAGCCAGGGA - 39 (R)
doi:10.1371/journal.pone.0114588.t002
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permeabilization were assessed using the fluorescence intensities of both the dyes
analysed by flow cytometry (Muse Cell Analyzer, Merck Millipore; Darmstadt,
Germany).
Determination of nuclear morphology
Changes in nuclear morphology were assessed after transfection with MB and in
lipofectamine-treated cells for 48 and 72 h. Cells were fixed with 4%
paraformaldehyde on 8-well chamber slides. After washing with PBS, cells were
incubated with DAPI 300 nM (Invitrogen Life Technologies, Carlsbad, CA, USA).
Life fluorescence analysis was realized with Eclipse E600FN Nikon microscope.
The fluorophore DAPI is a fluorescent label for the blue spectral region (excitation
and emission wavelengths of 360 and 460 nm, respectively) (magnification
406WD).
Statistical analysis
All experiments were performed in triplicate and results were analyzed by
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). Data were shown
as mean values¡ standard error of the mean (SEM) obtained from at least three
independent experiments. Statistical analyses were performed by Student’s t-test
or one-way ANOVA followed by the Bonferroni’s multiple comparison test.
Results
Survivin mRNA expression in different cell types
RT-PCR experiments followed by densitometry and quantification of electro-
phoresis bands clearly demonstrated that survivin was differentially expressed in
human melanoma cells compared to normal cells. Specifically, survivin mRNA
levels were significantly higher in A375 and 501 Mel cells than in BSMC
(p,0.001), while human melanocytes and monocytes did not express survivin
(Fig. 1). b-actin was used as housekeeping gene because its expression levels did
not significantly change in all of our experimental conditions.
MB specific binding to survivin mRNA
In vitro bioimaging was used to assess transfection of the MB via Lipofectamine
into different cell types tested and its target-specific structure opening with
fluorescence emission. Confocal microscopy of living cells clearly demonstrated
that MB transfection generated a fluorescence signal according to survivin
expression levels and time of exposure. Specifically, confocal microscopic images
of A375 and 501 Mel cells showed high signal intensity in these specific cell types
(Fig. 2) indicating that MB could cross the cell membrane, bind to survivin
mRNA and generate high fluorescence emission. Otherwise, the fluorescence
signal was significantly lower in the case of BSMC cells, while no fluorescence
Survivin-Targeting Molecular Beacon in Melanoma Cells
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could be detected in human melanocytes and monocytes (Fig. 2). Noteworthy, an
intense red fluorescent signal was observed (data not shown) when human
monocytes were transfected with the fluorescent probe. This demonstrated that
Lipofectamine was able to transfect both melanoma cells and normal cells (i.e.,
melanocytes and monocytes), and that the MB specifically opened with
fluorescence emission only in survivin mRNA positive cells (i.e., A375 and 501
Mel cells). Specificity of the bases forming the MB loop for survivin versus other
members of the IAP family was confirmed by BLAST analysis.
MB downregulation of survivin expression and protein synthesis
We performed real-time PCR experiments to quantitatively assess the effect of MB
on survivin gene expression in different cell types. Treatment with MB for 24 h
significantly decreased survivin expression by 79.3¡7.6% (p,0.01), as compared
to cells transfected with control (only lipofectamine) in A375 cells (Fig. 3A).
Prolonged cellular exposure to MB further decreased expression of survivin and
the maximum effect was reached after 72 h (-94¡1.6%, as compared to control).
These findings were also confirmed in 501 Mel cells in the same experimental
conditions (Fig. 3B).
Expression levels of survivin protein in A375 cells was assessed by western blot
and the bands on the blot image were analysed by densitometry. In A375 lysates,
the survivin antibody mainly labelled a band corresponding to an apparent
Fig. 1. Survivin gene espression in A375, 501 Mel, melanocytes, BSMC, and monocytes. Values were
expressed as mean ¡ standard error of the mean (SEM) from three separate experiments. ***p,0.001,
compared with melanocytes (ANOVA followed by the Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0114588.g001
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molecular weight of 16.5 KDa. Cell treatment with MB time-dependently
inhibited survivin protein expression by 44.3¡2.4, 66.1¡1.1, and 90.1¡1.8%
after 24, 48 and 72 h, respectively, as compared to control (Fig. 4).
MB induction of apoptosis
The ability of MB to induce apoptosis in human melanoma cells was investigated
by evaluating dissipation of mitochondrial membrane potential (DYm),
internucleosomal DNA fragmentation, and nuclear morphological changes.
Treatment with MB for 48 h induced a significant (p,0.001) variation in DYm
in about 35% of total cells in A375, suggesting the involvement of the intrinsic
pathway in the molecular mechanism of MB action. Otherwise, control
experiments demonstrated the absence of significant changes in DYm (Fig. 5A). A
representative dot plots in live, depolarized/live, depolarized/dead and dead phase
is showed in the upper panel in Fig. 5A.
Fig. 2. Confocal microscopy images of survivin expression in the cytoplasm of living cells. Cells were treated with 100 nM MB (red) and fluorescence
was measured at 1, 2 and 3 h following start of transfection. Confocal fluorescent images are shown in the left column, transmission DIC images in the
central column, while the merged images are also shown in the right column. The fluorescence images were obtained by using excitation and emission
wavelengths of 645 and 669 nm, respectively and an oil immersion objective (x40, NA51.3).
doi:10.1371/journal.pone.0114588.g002
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MB induced accumulation of histone-complexed DNA fragments in the
cytoplasmic fraction of A375 cell lysates after 48 and 72 h, while after 24 h it did
not significantly induce cell death (Fig. 5B). This is probably due to the fact that
major DNA fragmentation is a late event in apoptosis. According to this, DAPI
staining experiments showed that many A375 and 501 Mel cells exposed to MB
for 48 and 72 h exhibited nuclear condensation and chromatin fragmentation,
while human melanocytes did not (Fig. 5C). Noteworthy, increased formation of
multinucleated cells was observed in MB-treated cells, whereas control cells
showed normal nuclear morphology (data not shown).
MB enhancement of chemotherapy-induced apoptosis
To assess the ability of MB to increase the proapoptotic effects induced by DTX
and CisPt, A375 cells were pre-incubated with MB at 100 nM for 48 h, followed
Fig. 3. Real-time PCR assessment of survivin gene expression in (A) A375, and (B) 501 Mel cells. Cells
were transfected with lipofectamine-MB or treated with lipofectamine alone (Ctrl) and analyzed after 24, 48
and 72 h. Values were expressed as mean¡ standard of the mean (SEM) from three separate experiments.
*p,0.05, **p,0.01, ***p,0.001, (ANOVA followed by the Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0114588.g003
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by DTX at 10 nM or CisPt at 1 mM for 24 h. Apoptosis after single agent or
combination treatments was analyzed by measuring DYm. The combination of
MB with DTX or CisPt at low concentrations produced an effect greater than that
of each drug alone (Fig. 6). Specifically, the percentage mean values of depolarized
A375 cells after single DTX and MB treatments were 1.64¡0.72% and
16.34¡4.24%, respectively, as compared to control. It is worth mentioning that
MB plus DTX significantly (p,0.001) increased the percentage of depolarized cells
up to 33.28¡4.59%, compared to control (Fig. 6A). The statistical analysis also
highlighted a significant (p,0.01) DYm increase in combination versus single
agent treatments. In a similar manner, the percentage of depolarized cells after
treatment with single CisPt and MB was 10.64¡0.92% and 11.93¡2.76%,
respectively, whereas it was of 29.98¡4.09% after combination treatment
(Fig. 6B).
Discussion
Although depletion of survivin by siRNA has been previously reported to increase
the sensitivity of cancer cells to chemotherapy in vivo [23, 24], siRNA-based
therapeutics targeting survivin per se does not have the potential to detect cancer
cells. Our findings provide evidence of a novel potential strategy for both cancer
diagnosis and treatment. Specifically, we deeply characterized in vitro a MB that
conjugates the ability of imaging of survivin with the pharmacological silencing
activity in human melanoma cells (Fig. 7). The ability of the MB-lipofectamine
system to cross the cell membrane and to penetrate into the cytoplasm of A375
Fig. 4. Detection of survivin protein levels by Western Blot analysis in A375 cells. Cells were transfected
with lipofectamine-MB or treated with lipofectamine alone (Ctrl) and analyzed after 24, 48 and 72 h. Values
were expressed as mean ¡ standard of the mean (SEM) from three separate experiments. ***p,0.001,
(ANOVA followed by the Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0114588.g004
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and 501 Mel cells was clearly demonstrated in the current study by confocal
microscopy. Transfection of MB into human melanoma cells generated high
signal intensity from the cytoplasm, while no signal was detected in the
extracellular environment or in survivin-negative cells (i.e., human melanocytes
and monocytes). These findings demonstrate the diagnostic capability of the MB
that may have great potential to translate into clinical applications. In this regards,
a tumor-specific accumulation in the in vivo setting could be reached via
nanoparticle-delivered transfection, therefore permitting enhanced permeability
and retention effect in cancer tissues [25].
It is widely recognized that survivin expression in melanoma is inversely
correlated with patient survival [26]. Furthermore, high survivin expression is
associated with resistance to chemotherapeutic agents [8] and survivin-over-
Fig. 5. (A) Dissipation of the mitochondrial membrane potential (DYm) in A375 cells at 48 h. A representative dot plots in live, depolarized/live,
depolarized/dead and dead phase is showed in the upper panel, whereas the mean percentages of the total cell number for each cell status are reported in
the lower panel. Values were expressed as mean ¡ standard of the mean (SEM) from three separate experiments. ***p,0.001, as compared to control
(Student’s t-test). (B) Time-dependent fragmentation of internucleosomal DNA in A375 cells after MB treatment at 100 nM for 24, 48 and 72 h. Values were
expressed as mean ¡ standard of the mean (SEM) from three separate experiments. *p,0.05, **p,0.01, as compared to 24 h (ANOVA followed by the
Bonferroni’s multiple comparison test). (C) Nuclear morphology revealed by DAPI staining of A375, 501 Mel cells and human melanocytes transfected with
MB or treated with lipofectamine alone (Ctrl) at 48 and 72 h.
doi:10.1371/journal.pone.0114588.g005
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expressing melanoma cells have been reported to have a potential role in lung
metastasis [27, 28]. Therefore, the development of targeted contrast agents (such
as fluorescent probes) coupled with optical imaging techniques could allow to
characterize tumor progression in vivo with great sensitivity and selectivity.
The current study demonstrated the therapeutic potential of the tested MB.
This MB was already described in literature [20] for the detection and
quantification of survivin mRNA. However, no evidence was provided on its
silencing activity in pancreatic cancer cells [20, 29], whereas other works showed
that a partially homologous MB did not induce any variation in survivin
expression in human breast cancer cells [30].
Fig. 6. Dissipation of the mitochondrial membrane potential (DYm) induced by MB, cisplatin (CisPt)
and docetaxel (DTX), alone or in combination schedules, in A375 cells. Cells were preincubated with MB
at 100 nM for 48 h in the presence or absence of CisPt at 1 mM (A) or DTX at 10 nM (B) for 24 h. Values were
expressed as mean ¡ standard of the mean (SEM) from three separate experiments. *p,0.05, **p,0.01,
compared with MB alone; ##p,0.01, ###p,0.001, compared with CisPt or DTX alone; +++p,0.001,
compared with control (Ctrl), (ANOVA followed by the Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0114588.g006
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Concerning the molecular beacon tested in this work, we found that treatment
with MB markedly decreased survivin mRNA and protein expression associated
with activation of apoptosis. In line with evidence highlighting the central role of
mitochondrial survivin in the apoptotic machinery [31], we demonstrated that
MB, at nanomolar concentrations, induced a significant loss of mitochondrial
transmembrane potential in A375 cells. Furthermore, the increased formation of
multinucleated cells observed in the current study after transfection with MB is
also consistent with the critical role of survivin in the regulation of cytokinesis
[32, 33]. Indeed, survivin is a component of the chromosomal passenger complex,
which plays a role in chromosome condensation, interaction between kineto-
chores and microtubules at metaphase and midzone microtubule organization at
anaphase [33].
Concerning the mechanism of action, MB is a stem-loop hairpin-structured
oligonucleotide that works as an antisense oligonucleotide. In agreement with this
notion, selective inhibition of survivin expression by the antisense oligonucleotide
LY2181308 induced apoptosis, cell cycle arrest in the G2-M phase, and formation
of multinucleated cells [34].
Another interesting point that needs to be discussed regards the role of survivin
in chemoresistance [35]. For example, it has been reported that both docetaxel
and cisplatin induced accumulation of survivin in different types of tumors
including melanoma [36, 37], lung [38], breast [39], and gastric [40, 41] cancer.
We have found that in vitro combination treatment of MB and docetaxel or
cisplatin induced a greater rate of apoptosis than the sum of the single-treatment
rates in A375 cells, suggesting that targeting survivin has the potential to increase
the sensitivity of cancer cells to chemotherapeutics. The effect induced by
combination schedules appears to be additive because it is approximately the sum
of the percentage obtained from single treatments, both in terms of depolarized
cells (i.e., cells committed to die) and dead cells. Moreover, it is also possible that
survivin silencing may restore sensitivity to targeted therapy. In line with this
Fig. 7. Overview of theranostic properties of anti-survivin moleular beacon.
doi:10.1371/journal.pone.0114588.g007
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notion, it has been recently demonstrated that blood survivin mRNA positivity
was strongly related to a poor treatment outcome of EGFR-tyrosine kinase
inhibitors in non-small cell lung cancer patients [42].
Although general transfection techniques (including those employing lipo-
somes or dendrimers) might result in false positive signals, we demonstrated that
cellular lipofection of tested MB was specific with no false positive results. Indeed,
a bright red fluorescent signal was observed when cells that did not express
survivin (i.e., monocytes) were transfected with the linear probe (the same
fluorescent antisense oligonucleotide of MB lacking the quencher molecule), while
no signal was detected after MB transfection.
Taken together, our findings provide evidence of a novel potential anticancer
strategy for the simultaneous imaging and targeted therapy in human cutaneous
melanoma. The ability to image specific RNAs in vivo may offer new
opportunities in terms of development of clinical diagnostic procedures for the
early detection of cancer, pharmacological monitoring of silencing effect, and
follow-up after surgery or chemotherapy treatment.
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